JP2015506355A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506355A5
JP2015506355A5 JP2014549480A JP2014549480A JP2015506355A5 JP 2015506355 A5 JP2015506355 A5 JP 2015506355A5 JP 2014549480 A JP2014549480 A JP 2014549480A JP 2014549480 A JP2014549480 A JP 2014549480A JP 2015506355 A5 JP2015506355 A5 JP 2015506355A5
Authority
JP
Japan
Prior art keywords
alkyl
group
heterocyclyl
substituted
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014549480A
Other languages
English (en)
Japanese (ja)
Other versions
JP6130399B2 (ja
JP2015506355A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/077027 external-priority patent/WO2013098375A1/en
Publication of JP2015506355A publication Critical patent/JP2015506355A/ja
Publication of JP2015506355A5 publication Critical patent/JP2015506355A5/ja
Application granted granted Critical
Publication of JP6130399B2 publication Critical patent/JP6130399B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014549480A 2011-12-30 2012-12-28 新規アゼチジン誘導体、医薬組成物およびそれらの使用 Expired - Fee Related JP6130399B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11196170 2011-12-30
EP11196170.2 2011-12-30
PCT/EP2012/077027 WO2013098375A1 (en) 2011-12-30 2012-12-28 New azetidine derivatives, pharmaceutical compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2015506355A JP2015506355A (ja) 2015-03-02
JP2015506355A5 true JP2015506355A5 (enExample) 2016-02-25
JP6130399B2 JP6130399B2 (ja) 2017-05-17

Family

ID=47553036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549480A Expired - Fee Related JP6130399B2 (ja) 2011-12-30 2012-12-28 新規アゼチジン誘導体、医薬組成物およびそれらの使用

Country Status (13)

Country Link
US (1) US8623860B2 (enExample)
EP (1) EP2797884B1 (enExample)
JP (1) JP6130399B2 (enExample)
KR (1) KR20140115307A (enExample)
CN (1) CN104093705A (enExample)
AU (1) AU2012360797A1 (enExample)
BR (1) BR112014015845A8 (enExample)
CA (1) CA2861013A1 (enExample)
EA (1) EA201400771A1 (enExample)
IL (1) IL232914A0 (enExample)
MX (1) MX2014007897A (enExample)
PH (1) PH12014501514A1 (enExample)
WO (1) WO2013098375A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2648820T3 (es) 2011-05-10 2018-01-08 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de los canales de sodio
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (enExample) 2011-07-01 2018-04-28
WO2014061693A1 (ja) * 2012-10-17 2014-04-24 塩野義製薬株式会社 新規非芳香族炭素環又は非芳香族複素環誘導体
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
CN103483273B (zh) * 2013-09-12 2015-11-25 浙江工业大学 6-甲基-5-氟-2,4-嘧啶二胺类化合物及其制备与应用
JPWO2015056782A1 (ja) 2013-10-17 2017-03-09 塩野義製薬株式会社 新規アルキレン誘導体
EP3116501A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
EP3116870A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2952862A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10392378B2 (en) 2014-12-23 2019-08-27 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
NZ741093A (en) 2015-10-06 2022-12-23 Proteostasis Therapeutics Inc Compounds, compositions, and methods for modulating cftr
BR112018070747B1 (pt) 2016-04-07 2024-01-09 Proteostasis Therapeutics, Inc Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
EP3472156B1 (en) 2016-06-21 2023-06-07 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CN110776504B (zh) * 2019-11-29 2021-07-30 扬州工业职业技术学院 一种苯异噁唑乙氧基环丁胺衍生物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
DE102005055726A1 (de) 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
KR20080087833A (ko) 2005-12-21 2008-10-01 쉐링 코포레이션 히스타민 h3 길항제로서 유용한 페녹시피페리딘 및 이의유사체
JP2009539884A (ja) * 2006-06-12 2009-11-19 メルク フロスト カナダ リミテツド ステアロイル−コエンザイムaデルタ−9デサチュラーゼのインヒビターとしてのアゼチジン誘導体
EP2350054A4 (en) 2008-10-17 2012-03-28 Merck Canada Inc AZETIDINE DERIVATIVES AS INHIBITORS OF THE STEAROYL COENZYME A DELTA 9 DESATURASE
US20100280067A1 (en) 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
EA021698B1 (ru) 2010-04-27 2015-08-31 Такеда Фармасьютикал Компани Лимитед Производные бициклических соединений и их применение в качестве ингибиторов acc
SG185515A1 (en) * 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors

Similar Documents

Publication Publication Date Title
JP2015506355A5 (enExample)
CN105745206B (zh) 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
JP6648137B2 (ja) ヘテロ環式誘導体およびその使用
JP4722851B2 (ja) キノリンカリウムチャネル阻害剤
RU2013149174A (ru) Новое имидазооксазиновое соединение или его соль
JP2015500856A5 (enExample)
AU2012361581B2 (en) Effect potentiator for antitumor agents
RU2012104700A (ru) Азабициклосоединение и его соль
RU2012129168A (ru) Производные оксазина
RU2010126105A (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства
JP2015503540A5 (enExample)
RS54339B1 (sr) Novi antimalarijski agensi
IL211291A (en) Picolinamide Compounds, Pharmaceuticals Containing Them, and Their Use in the Preparation of Cancer Drugs
JP2013509392A5 (enExample)
JP2007506743A (ja) イソキノリン系カリウムチャンネル阻害薬
RU2002131885A (ru) Антраниламиды и их применение в качестве лекарственных средств
RU2012108423A (ru) Ацилгуанидиновые производные с азотсодержащим циклом
JP2014516070A5 (enExample)
AU2009335221A1 (en) Toluidine sulfonamides and their use
JP7203846B2 (ja) 置換アゼチジンジヒドロチエノピリジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
JP2013540714A5 (enExample)
JP2015500267A5 (enExample)
CN105367582B (zh) 银杏内酯b衍生物及其在药物中的应用
MX2013012577A (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
JP2020500920A (ja) 置換ピラゾロアゼピン−4−オンおよびそれらのホスホジエステラーゼ阻害剤としての使用